Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Vaxart sent this email to their subscribers on December 2, 2024.

December 2, 2024 4:01 PM EST

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

View this release →

Or click here to view all releases.

Text-only version of this email

Vaxart, Inc. December 2, 2024 4:01 PM EST Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate View this release → Or click here to view all releases.

Show all

The Latest Emails Sent By Vaxart

Stock Quote Notification for Vaxart, Inc.

Stock Quote Notification for Vaxart, Inc.

Stock Quote Notification for Vaxart, Inc.

Stock Quote Notification for Vaxart, Inc.

Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs

Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial

Stock Quote Notification for Vaxart, Inc.

Stock Quote Notification for Vaxart, Inc.

Weekly Summary Alert for Vaxart, Inc.

Weekly Summary Alert for Vaxart, Inc.